MPL - Medicare private
2026
...............................
ASX:MPL (Medibank Private) has delivered resilient but maturing performance over the last 5 years, characterized by a steady share price, excellent capital management, and high profitability, despite short-term margin fluctuations. [1, 2, 3, 4, 5]
Profitability & Performance
- Profit: Medibank has remained a highly profitable, cash-generating business. In the last 12 months, it earned roughly $463.4 million in net income on $8.77 billion in revenue. While net margins swung from 6.27% (FY2021) down to 4.17% (FY2023) and back up during the period, underwriting profitability has generally remained resilient. [1, 2, 3]
- ROE: Return on Equity (ROE) has stayed exceptionally strong, generally hovering around the 20% to 26% mark, which sits favorably near its historical 10-year median. [1, 2]
For Medibank Private Limited, the key takeaway is not the exact year-to-year movement but the consistency:
- Average ROE over the decade: approximately 21%.
- Only one weak year: FY2023, when ROE fell to around 15% due to higher claims inflation and normalization after unusually favourable COVID-era conditions.
- Recovery was rapid: ROE returned above 21% in FY2024 and FY2025.
- Capital-light business model: Health insurance requires relatively little equity capital, allowing MPL to maintain ROEs well above the ASX average.
- Current ROE: around 20–22%, which places it among the stronger quality franchises on the ASX.
From a quality-investing perspective, MPL scores highly on:
- Sustained ROE above 20%.
- Very low financial leverage.
- Strong free cash generation.
- Consistent fully franked dividends.
The main risk to future ROE is health claims inflation outpacing premium increases approved by the government, which can compress margins for periods of time.
- Earnings. Over the last 10 years, Medibank Private (ASX: MPL) earnings have seen consistent growth, though they fluctuated recently. The net profit after tax reached roughly $500.8 million in FY25, representing a 2% compound annual growth rate (CAGR) over the decade. Its adjusted earnings per share (EPS) sits around 18.2 cents. [1, 2, 3]
- A detailed view of MPL’s financial performance over the past decade highlights this trend:Historical Earnings
- FY25 Full-Year Results: Net profit after abnormals landed at $500.8 million. Health insurance operating profit continued to drive revenue, though cybercrime-related impacts remained a historical focus. [1, 2]
- FY24 Full-Year Results: The company recorded a solid net profit after abnormals of $492.5 million, bouncing back robustly from the previous year. [1]
- FY23 Full-Year Results: Net profit was heavily impacted by the late 2022 cyber incident, with statutory net profit dropping down to approximately $333 million. [1]
- FY16–FY22 Period: MPL exhibited steady, reliable profit growth, with health insurance operating profits growing consistently, except for temporary disruptions during the peak COVID-19 pandemic years. [1]
Debt & Financial Health
- Low Debt: Medibank’s balance sheet is a major strength. The company operates with a very low Debt to Equity ratio of around 12%.
- Net Cash Position: Total cash holdings have consistently exceeded total debt over the last 5 years. This net-cash position provides strong financial stability and high liquidity. [1, 2]
Key Observations & Outlook (2026- forward)
- Maturing Market: The private health insurance sector in Australia is highly penetrated, limiting massive organic growth. To counter this, Medibank has been aggressively expanding into its 'Medibank Health' division (including the acquisitions of Myhealth and Better Medical) to secure new revenue streams. [1]
- Medibank Private (ASX: MPL) faces several material risks in the coming years, primarily driven by structural claims inflation, cost-of-living pressures, and ongoing regulatory constraints. These factors directly impact their margins and ability to grow policyholder bases. [1, 2]The primary challenges Medibank must navigate include:
- Claims & Medical Inflation: Driven by an aging population, more frequent hospital treatments, and the adoption of expensive new medical technologies, healthcare costs are rising faster than general inflation. This places constant pressure on underwriting margins. [1]
- Affordability & Cost-of-Living Pressures: As household budgets are stretched, policyholders may downgrade their level of coverage or drop private health insurance entirely to save money. The subsequent need to raise premiums to cover costs limits their ability to increase revenue without triggering mass customer attrition. [1, 2, 3]
- Regulatory Intervention: The Federal Government strictly regulates and must approve all annual premium rate increases. During periods of high claims inflation, delayed or denied premium hikes restrict MPL’s pricing power. [1]
- Intense Competition: The rise of third-party price aggregators and alternative mutual health funds makes it easier for customers to shop around for cheaper plans, leading to fierce member-retention challenges. [1, 2, 3]
- Cybersecurity and Data Obligations: Following the highly publicized 2022 breach, MPL is carrying elevated technology and compliance costs. Lingering reputational impacts and ongoing class-action or regulatory lawsuits (such as proceedings with the OAIC) pose material tail risks to their bottom line. [1, 2]
- Execution Risk in New Verticals: Medibank is expanding its footprint outside of traditional insurance into primary care and health services (e.g., the integration of the Better Medical clinic network). Operating these physical health hubs introduces new operational and capital management risks. [1, 2]
......................
The 10-year historical Price-to-Earnings (P/E) ratio for Medibank Private Limited (ASX: MPL) has fluctuated over a wide spectrum, ranging from a historical low of 14.38 to a peak of 43.0. Over the last decade, Medibank's historical trailing twelve months (TTM) median P/E ratio sits at 20.25. [1, 2]
As of July 2026, Medibank is trading at an elevated valuation with a current P/E ratio of approximately 29.7x to 30.0x, which is roughly 47% above its 10-year historical average. [1]
Annual Historical P/E Ratios (10-Year Trend)
| Year | P/E Ratio (End of Year / Fiscal) | Valuation Context & Market Drivers |
|---|---|---|
| Current (July 2026) | 29.7x – 30.1x | Premium valuation driven by elevated market caps and robust policyholder growth. |
| 2025 | 43.0 | Record high P/E ratio sparked by surging share price valuations vs compressed underlying margins. |
| 2024 | 29.6 | Valuation recovery post-cyberattack fallout as client numbers normalized. |
| 2023 | 26.2 | Under pressure due to the remediation costs and regulatory impacts of the late-2022 cyber breach. |
| 2022 | 29.5 | High-growth cycle pushed valuations higher as interest rate hikes boosted investment income portfolios. |
| 2021 | 21.5 | Normalized trading volume during late COVID-19 pandemic phases. |
| 2020 | 19.8 | Lower underwriting utilization during COVID lockdowns offset premium growth. |
| 2019 | 21.2 | Steady market performance aligned closely with its long-term average historical trend line. |
| 2018 | 17.5 | One of the lowest decade valuations, driven by regulatory uncertainty preceding federal elections. |
| 2017 | 20.4 | Moderate trading tracking the broader financial sector average indices. |
| 2016 | 22.1 | Steady multi-year baseline stabilization period following its 2014 initial public offering (IPO). |
Key Valuation Statistics (Past 10 Years)
- 10-Year High: 43.0 (Recorded at the conclusion of 2025).
- 10-Year Median: 20.25.
- 10-Year Low: 14.38.
- Sector Peer Comparison: At ~30x earnings, Medibank trades at a significant premium compared to the broader Australian Insurance Industry average of 12.2x to 19.7x, though it sits below smaller peers like ClearView Wealth (~77x). [1, 2, 3, 4, 5]
Underlying Valuation Metrics
- Forward Outlook: Medibank's forward P/E ratio is projected to fall back to around 20.6x to 20.8x based on forecast consensus earnings growth of nearly 10%. [1, 2, 3]
- Dividend Yield Intersect: Medibank remains a favorite for income investors, paying a trailing yield of 3.3% to 4.2%. It has been increasing steadily since 2020 However, the current high payout ratio (around 99% to 110% of earnings) places intense pressure on earnings growth to sustain the premium valuation. [1, 2, 3]
..............................
ROIC vs WACC 2026
Over the last 10 years, Medibank Private Limited (ASX:MPL) has consistently maintained a strong economic spread, with a high Return on Invested Capital (ROIC) significantly outperforming its Weighted Average Cost of Capital (WACC). [1]
- ROIC: Averaged roughly 12% to 20% over the decade (currently sitting at approximately 12.37% to 18.71%).
Value Creation and Business Performance
- Economic Spread: MPL's ROIC has continuously exceeded its WACC by a wide margin (often a positive spread of 7% to 14%+), indicating strong and consistent economic value creation for shareholders. [1, 2, 3]
- Capital Efficiency: As a dominant player in Australian private health insurance, low management expense ratios and stable premium pricing power have allowed Medibank to earn robust excess returns relative to its cost of capital over the long term. [1]
-------------------
Buffet style analysis - Sept 2026 - ARGO vs MBF vs NIB
Analyzing Argo Investments (ARG), NIB Holdings (NHF), and Medibank Private (MPL) from a Warren Buffett value-investing framework requires evaluating their structural competitive moats, pricing power, capital allocation, and valuation margins.
The financial snapshot for these three entities is summarized below:
| Metric | Argo Investments (ASX: ARG) | NIB Holdings (ASX: NHF) | Medibank Private (ASX: MPL) |
|---|---|---|---|
| Current Price | $9.13 | $6.47 | $4.55 |
| P/E Ratio | 26.63 | 17.04 | 19.62 |
| Dividend Yield | ~3.8% | ~4.48% | ~4.22% |
| 10-Year Growth Profile | Stable matching ASX200 index (~26.6% total capital return over 10Y) | Dynamic expansion via geographic and NDIS segments | Slower, defensive market leader expansion |
| Franking | 100% | 100% | 100% |
1. The Business Moat & Predictability
Buffett prioritizes an easily understandable business model with a durable competitive advantage (a "moat") that protects long-term earnings.
- ASX: ARG (The Institutional Pass-Through Moat): Argo operates as a Listed Investment Company (LIC). Its moat is structural rather than product-based: an ultra-low management fee (~0.14%) and a highly trusted 80-year-old brand. However, as an investment vehicle, its growth is capped by the collective returns of the broader Australian share market. Buffett would view this as a low-risk "holding company," but it lacks a unique corporate pricing lever. [1]
- ASX: NHF (The Agile Challenger Moat): NIB acts as an aggressive private health insurer. It builds its moat through low-cost operations, highly flexible product tailoring for younger demographics, and adjacent expansion vectors like corporate travel insurance and National Disability Insurance Scheme (NDIS) plan management. [1]
- ASX: MPL (The Toll-Bridge Scale Moat): Medibank is the definition of a Buffett-style corporate "toll-bridge." Holding the largest private health insurance market share in Australia, its primary moat is pure scale economy. This massive data pool allows for efficient underwriting, while its brand leverage drives strong corporate partner relationships.
2. Pricing Power & Inflation Resilience
Buffett famously noted that the single most important decision in evaluating a business is its pricing power—the ability to raise prices without losing market share to competitors.
- The Insurers (NHF & MPL): Both companies boast excellent, highly defensive pricing power. Private health insurance in Australia functions as an essential utility due to structural government incentives (such as the Medicare Levy Surcharge and Lifetime Health Cover loading). Medibank and NIB regularly adjust their underlying premiums upward. These adjustments are heavily insulated because consumers face a high psychological hurdle to switching healthcare coverage. [1]
- The Investor (ARG): Argo lacks independent operational pricing power. It functions as a price-taker reliant on the dividend distribution policies of large cap entities like BHP, Commonwealth Bank, and Wesfarmers. [1]
3. 10-Year Dividend Sustainability & Growth
A Buffett evaluation focuses heavily on normalized free cash flows and regular dividend increases driven by real earnings growth rather than debt expansion.
- ARG: Offers exceptionally predictable, fully franked dividend income stream smoothed out over multi-year periods using retained profit reserves. Dividend growth mimics long-term inflation and Australian GDP growth rather than aggressive expansion.
- NHF: Delivers volatile but generally higher dividend growth. Management aggressively targets capital reinvestment into high-margin segments, leading to an increasing dividend payout over a 10-year horizon, though tied to cyclical medical claim loss ratios.
- MPL: Operates with a highly disciplined, steady payout ratio (typically targeting 75% to 85% of underlying net profit). Capital expenditure needs are low, allowing Medibank to reliably function as a premium income producer. [1]
4. Buffett Style Verdict
- If you want a compounder at a reasonable price: NIB Holdings (NHF) closely fits the traditional Berkshire template. Its cheaper forward multiples (P/E of 17.04) combined with a stronger historical capacity to outgrow the broader economy provide a favorable profile for active capital expansion.
- If you want a fortress cash cow: Medibank (MPL) represents the stable, wide-moat market leader choice. While it trades at a slight valuation premium compared to NIB (P/E of 19.62), its large-scale stability reduces structural downside risks.
..............................
More buffett analysis
Medibank Private Limited (ASX: MPL) demonstrates highly efficient operational performance, with its current Return on Equity (ROE) reaching 28.16% as of June 2026. [1]
This is 17% above its 10-year median of 24.05%, driven by a strong rebound in underwriting profits and premium revenue growth. [1, 2]
When evaluated through a Warren Buffett investment framework, Medibank showcases the traits of a high-quality "capital-light" compounder, though its capital distribution strategy shifts away from traditional Berkshire habits.
📈 Historical ROE Trend Analysis
Medibank’s recent fiscal data highlights a notable cyclical recovery and an expanding profit engine:
| Metric | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Return on Equity (ROE) | 28.16% | 23.33% | 23.20% | 14.73% | 20.45% |
| Net Profit After Tax (NPAT) | $638.7M | $500.8M | $492.5M | — | — |
| Asset Turnover Ratio | 1.97x | 1.82x | 1.84x | 1.72x | 1.68x |
- The Operational Turnaround: Between FY22 and FY23, Medibank's profitability dipped severely due to a sharp drop in operating margins and fluctuating medical loss ratios. However, from FY24 through FY26, the company successfully scaled premium pricing alongside an improving asset turnover ratio (jumping from 1.72x to 1.97x), optimizing how efficiently it squeezes revenue from its balance sheet. [1, 2]
🏛️ Capital Allocation vs. Buffett Benchmarks
1. The 20% ROE Floor (Benchmark: Passed)
- Buffett Rule: Buffett explicitly favors businesses that can generate a consistent ROE above 20% without relying on excessive leverage. [1]
- Medibank Performance: Medibank easily satisfies this criterion, maintaining a normalized 10-year median of 24.05% and expanding its current trajectory past 28%. [1]
2. The $1 Retained Earnings Test (Benchmark: Neutral/Modified)
- Buffett Rule: For every dollar of earnings management chooses to retain rather than pay out, the company must create at least one dollar of market value.
- Medibank Performance: Medibank operates an incredibly lean, capital-light framework. Because health insurance does not require heavy capital expenditures to build physical infrastructure, it does not need to retain vast quantities of cash to grow. [1]
3. Dividend Payout Strategy (Benchmark: Divergent but Rational)
- Buffett Rule: Berkshire Hathaway famously pays $0 in dividends, preferring to retain 100% of profits to reinvest at high rates of return.
- Medibank Performance: Medibank maintains an aggressive dividend profile, with a 78% payout ratio in FY26 (and over 90% in FY25). While this diverges from Buffett's personal holding structures, it aligns perfectly with the Australian tax regime. Due to franking credits, ASX mature compounders maximize shareholder value by returning cash to investors, who receive tax offsets that don't exist in the US market. [1, 2]
⚖️ Investor Takeaway
Medibank matches the structural DNA of a Buffett business: it produces high-margin, recurring revenue, exhibits strong pricing power, and commands exceptional returns on equity. While it chooses to pay out its profits via dividends rather than retaining them for compounding acquisitions, this remains an optimal, tax-efficient framework for an ASX-listed giant.
........
No comments:
Post a Comment